Alnylam Pharmaceuticals reported for 2021

Alnylam Pharmaceuticals' GAAP loss for 2021 was $852.824 million, down 0.6% from $858.281 million in the previous year. Revenue increased 71.3% to $844.287 million from $492.853 million a year earlier.